IADR Abstract Archives

Organogold Compounds Unleash Cell Death by Opening Mitochondrial Channels

Objectives: We previously screened synthetic organogold compounds for anti-tumor activity in oral carcinoma cells. Here we aimed to study these compounds’ mechanism of action. Based on our previous results, we hypothesized that the organogold compounds acted on mitochondria and induced opening of the mitochondrial apoptosis-induced channel (MAC) or the mitochondrial permeability transition pore (mPTP), which are located in the mitochondrial outer and inner membranes, respectively. Opening of either channel commonly results in release of factors from the mitochondrial intermembrane space into the cytosol, which causes cell death.

Methods: Organogold compounds IV and V induced death in Bak-/-Bax-/- double-knockout (DKO) and parental mouse embryonic fibroblasts (MEF). Bax and Bak are integral components of MAC. The cytotoxicity of the two compounds on both cell lines was assessed using alamar blue viability assays. The compounds’ mechanism in causing cell death in the parental cells was investigated by examining several markers for apoptosis and necrosis using fluorescence microscopy, including release of mitochondrial proteins, mitochondrial depolarization and changes in cell shape and nuclear morphology. 

Results: Compound IV was more cytotoxic than compound V in either DKO or parental MEFs. However, the effect of compound IV was substantially attenuated in DKO cells, which suggested involvement of MAC. Furthermore, the treatments caused mitochondrial depolarization, which not only reinforced the involvement of mitochondrial-dependent pathways, but also suggested a role for mPTP. More experiments are underway to further examine the exact mechanisms by which MAC and mPTP are induced, especially in cancer cells. 

Conclusions: MAC and mPTP are potential targets for chemotherapy since their involvement in the mitochondrial death pathways has been shown. This project is significant because it identifies new targets to increase the efficacy of current cancer treatments. Furthermore, it examines the mechanisms and evaluates the potential of organogold compounds as anti-tumor drugs.

Division: IADR/AADR/CADR General Session
Meeting: 2013 IADR/AADR/CADR General Session (Seattle, Washington)
Location: Seattle, Washington
Year: 2013
Final Presentation ID: 1764
Abstract Category|Abstract Category(s): Clinical and Translational Science Network
Authors
  • Ng, Jacqueline  ( New York University, New York, NY, USA )
  • Hsu, Hans  ( New York University, New York, NY, USA )
  • Peixoto, Pablo  ( Weill Medical College of Cornell University, New York, NY, USA )
  • Contel, Maria  ( Brooklyn College, City University of New York (CUNY), Brooklyn, NY, USA )
  • Kinnally, Kathleen  ( New York University, New York, NY, USA )
  • SESSION INFORMATION
    Poster Session
    Clinical and Translational Research
    03/22/2013